Misoprostol is an effective noninvasive method to complete abortion in missed abortions, a new meta-analysis reveals. Moreover, sublingual doses of 600 µg or vaginal doses of 800 µg may potentially be good first doses.
Exposure to statins may lower the risk of hepatic decompensation and mortality, as well as reduce portal hypertension, in patients with chronic liver diseases (CLDs), according to a systematic review and meta-analysis.
The norepinephrine transporter (SLC6A2, NET) variant rs2242446/T-182C shows potential as a biomarker to predict the possibility of remission with venlafaxine in older adults with major depression, a recent study has found.
The development of resistance to cytarabine is associated with increased sensitivity to glucocorticoids in acute myeloid leukaemia (AML) patients with wild-type Fms-Related Tyrosine Kinase 3 (FLT3) mutation, a study has shown.
Conjugated oestrogens/bazedoxifene (CE/BZA) may reduce hot flush frequency by approximately half after around 8 to 10 days of treatment, according to a posthoc analysis. Sustained improvement can be achieved with continued treatment.
Use of intravenous morphine in emergency department patients diagnosed with acute heart failure (AHF) is associated with increased 30-day mortality, with the risk especially higher during the first 3 days, a study suggests.
Short-term intraocular pressure (IOP) elevation occurs from 3 to 7 hours after phacoemulsification in eyes with primary open-angle glaucoma (POAG). Administration of oral acetazolamide 1 hour before surgery significantly lowers the IOP elevation from 1 to 24 hours, while administration 3 hours postoperatively reduces the IOP elevation ≥5 hours after surgery, according to a study.
Combination therapy with methotrexate (MTX) and adalimumab, a human anti–tumour necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, according to a recent report.
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.